Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)
Recruiting now · Phase 1/Phase 2
Conditions studied: Stargardt Disease, Cone Rod Dystrophy, Juvenile Macular Degeneration, Stargardt Disease 1
In brief
This study is an open-label, single ascending dose clinical trial in participants who have ABCA4-related retinopathies. This is the first-in-human clinical trial in which ACDN-01 will be evaluated for safety, tolerability, and preliminary efficacy following a single subretinal injection of ACDN-01.
Key facts
- Study ID
- NCT06467344
- Run by
- Ascidian Therapeutics, Inc
- People needed
- 15
- Starts
- 2024-06-11
- Expected to finish
- 2030-12-01
- Last updated by the study team
- 2025-12-02
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of San Francisco — San Francisco, California, United States (enrolling)
- Vitreo Retinal Associates — Gainesville, Florida, United States (enrolling)
- Bascom Palmer Eye Institute — Miami, Florida, United States (enrolling)
- Wilmer Eye Institute at John Hopkins — Baltimore, Maryland, United States (enrolling)
- Massachusetts Eye and Ear — Boston, Massachusetts, United States (enrolling)
- University of Michigan Kellogg Eye Center — Ann Arbor, Michigan, United States (enrolling)
- Cincinnati Eye Institute — Cincinnati, Ohio, United States (enrolling)
- Casey Eye Institute OHSU — Portland, Oregon, United States (enrolling)
- Retina Foundation of the Southwest — Dallas, Texas, United States (enrolling)
- Retina Consultants of Texas — Houston, Texas, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.